Synergy CHC Corp. SNYR
requires, for purposes of this section, the terms "we," "us," "the Company" or "Synergy"
refer to Synergy CHC Corp.
health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain
health supplement (this study was performed independently and is not related to any U.S. Food and Drug Administration ("FDA")
Last close
0.10
2026-09-04
Market cap
$1.5M
2026-03-31 share count
52-week range
0.08 - 2.96
Valuation FY2025 figures against the last close
P/S0.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.27
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4M | $34.8M | $42.8M | — | $29.4M | $33.8M | $35.6M | $34.8M | $13.5M | $9.2K |
| Cost of revenue | $10.1M | $11.2M | $10.7M | — | $9.1M | $11.0M | $9.8M | $10.2M | $5.3M | $5.6K |
| Gross profit | $20.3M | $23.6M | $32.1M | — | $20.2M | $22.8M | $25.8M | $24.6M | $8.1M | $3.5K |
| SG&A | $8.8M | $4.7M | $6.1M | — | $5.5M | $7.2M | $8.4M | $8.0M | $3.4M | $961.6K |
| Total operating expenses | $28.8M | $17.8M | $21.3M | — | $28.2M | $27.7M | $24.0M | $21.7M | $7.7M | $961.6K |
| Operating income | -$8.5M | $5.8M | $10.8M | — | -$8.0M | -$4.9M | $1.8M | $2.9M | $486.0K | -$958.1K |
| Interest expense | $5.9M | $4.1M | $1.7M | — | — | $1.1M | $1.0M | $1.6M | $958.7K | $2.0K |
| Pre-tax income | -$12.2M | $2.2M | $6.6M | — | -$9.1M | -$6.4M | $815.6K | $148.2K | -$7.1M | -$960.1K |
| Income tax | $117.5K | $102.1K | $235.0K | — | $131.5K | $247.7K | $316.0K | $944.4K | $389.9K | $0 |
| Net income | -$12.3M | $2.1M | $6.3M | — | -$9.2M | -$6.2M | $499.6K | -$796.2K | -$7.5M | -$960.1K |
| EPS, basic | -1.27 | 0.28 | 0.86 | — | -0.10 | -0.07 | 0.01 | — | — | — |
| EPS, diluted | -1.27 | 0.28 | 0.86 | — | -0.10 | -0.07 | 0.01 | -0.01 | -0.11 | -0.01 |
| Shares, diluted (wtd. avg.) | $9.7M | $7.6M | $7.4M | — | $89.9M | $89.9M | $89.2M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.6M | $687.9K | $732.5K | $2.5M | $1.2M | $459.7K | $2.0M | $2.5M | $3.6M | $338 |
| Receivables | $3.2M | $5.3M | $2.1M | — | $1.4M | $4.5M | $4.3M | $2.2M | $4.0M | $2.9K |
| Inventory | $3.7M | $1.7M | $3.7M | — | $1.9M | $2.7M | $2.8M | $1.1M | $686.7K | $26.1K |
| Total current assets | $10.0M | $16.1M | $11.8M | — | $5.0M | $8.9M | $10.4M | $7.3M | $9.3M | $55.4K |
| Property, plant and equipment | — | — | — | — | $135.9K | $269.8K | $293.2K | $257.4K | $12.0K | — |
| Goodwill | — | — | — | — | — | $7.8M | $7.8M | $7.8M | $11.5M | — |
| Other intangibles | $150.0K | $283.3K | $416.7K | — | $7.6K | $3.0M | $5.5M | $5.1M | $5.9M | — |
| Total assets | $10.2M | $16.3M | $12.2M | — | $5.2M | $20.0M | $24.0M | $20.5M | $26.8M | $55.4K |
| Accounts payable | $6.4M | $5.2M | $11.7M | — | $4.7M | $8.4M | $4.3M | $4.6M | $5.0M | $74.6K |
| Short-term debt | — | $4.0M | $2.1M | — | — | $28.2K | $0 | $750.0K | $750.0K | $6.4K |
| Total current liabilities | $8.2M | $17.2M | $14.0M | — | $10.1M | $10.4M | $7.1M | $12.2M | $15.4M | $181.0K |
| Long-term debt | $25.1M | $7.5M | $13.1M | — | — | — | — | — | — | — |
| Total liabilities | $33.3M | $33.0M | $39.5M | — | $10.4M | $16.0M | $14.6M | $13.4M | $21.3M | $181.0K |
| Retained earnings | -$56.4M | -$44.1M | -$46.2M | — | -$24.2M | -$15.0M | -$8.9M | -$9.4M | -$8.6M | -$1.0M |
| Total equity | -$23.1M | -$16.6M | -$27.3M | -$33.5M | -$5.2M | $4.0M | $9.4M | $7.1M | $5.4M | -$125.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.6M | -$4.8M | $421.7K | — | $2.9M | $1.3M | -$831.1K | $6.0M | -$644.3K | -$489.2K |
| Depreciation and amortisation | — | $133.3K | $33.3K | — | $133.9K | $152.5K | $108.1K | $44.5K | $1.5K | $0 |
| Stock-based compensation | $136.2K | — | — | — | $201.2K | $441.0K | $1.5M | $2.2M | $551.7K | $322.2K |
| Capital expenditure | — | — | — | — | — | $129.1K | $153.0K | $302.2K | $7.8K | — |
| Investing cash flow | — | — | — | — | — | -$198.0K | -$1.9M | -$2.3M | -$4.4M | — |
| Financing cash flow | $4.7M | $4.8M | -$2.1M | — | -$2.0M | -$2.9M | $2.3M | -$4.8M | $8.7M | $486.3K |
| Dividends paid | — | — | — | — | — | — | — | — | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-050246.
Others in SIC 2833
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | $5.12B | — | — |
| TRLV | Trulieve Cannabis Corp. | $2.33B | — | -0.4% |
| CRON | Cronos Group Inc. | $1.20B | — | 24.6% |
| TLRY | Tilray Brands, Inc. | $612.9M | — | 11.5% |
| CGC | Canopy Growth Corp | $411.5M | — | — |
| USNA | USANA HEALTH SCIENCES INC | $276.4M | 25.8x | 8.3% |
| NAGE | Niagen Bioscience, Inc. | $250.8M | 15.8x | 29.9% |
| FTLF | FITLIFE BRANDS, INC. | $92.2M | 15.6x | 26.4% |